Skip to Content
Close Icon

COVID-19 Vaccine

*THE CENTER FOR DISEASE CONTROL AND PREVENTION (CDC) ENDORSES THE ADMINISTRATION OF A BOOSTER DOSE OF ALL 3 AVAILABLE COVID-19 VACCINES  IN CERTAIN POPULATIONS AND THOSE IN HIGH RISK OCCUPATIONAL AND INSTITUTIONAL SETTINGS*

 

On October 20th, 2021 the FDA and CDC have expanded the use of Booster doses of the Pfizer-BioNTech COVID-19 vaccine, the Moderna COVID-19 vaccine and the Janssen (Johnson & Johnson) COVID-19 vaccine in eligible patient populations. 

For individuals who received a Pfizer-BioNTech or Moderna COVID-19 vaccine, the following groups are eligible for a booster shot at 6 months or more after completion of their initial vaccination series:

Individuals eligible for the Pfizer-BioNTech or Moderna COVID-19 booster dose are:

• People 65 years and older 

• Residents of long-term care facility age 18 years or older

• Age 18 years or older with one or more of the following conditions due to increased risk of moderate or severe illness or death from the virus that causes COVID-19:

1. Cancer (current or in remission, including 9/11 related cancer

2. Chronic kidney disease

3. Pulmonary disease, including but not limited to, COPD, asthma, pulmonary fibrosis, cystic fibrosis, pulmonary embolism, pulmonary hypertension, and 9/11 related pulmonary diseases

4. Intellectual and developmental disabilities including Down Syndrome

5. Heart conditions, including but not limited to heart failure, coronary artery disease, cardiomyopathies, or hypertension (high blood pressure)

6. Immunocompromised state (weakened immune system) including but not limited to solid organ transplant or from blood or bone marrow transplant, immune deficiencies, HIV, use or corticosteroids, use of other immune weakening medicines

7. Overweight and obesity

8. Pregnancy

9. Sickle cell disease or thalassemia

10. Type 1 or Type 2 diabetes mellitus

11. Stroke or cerebrovascular disease (affects blood vessels and blood supply to the brain)

12. Neurologic conditions including but not limited to Alzheimer's disease or dementia

13. Chronic liver disease

14. Mental health conditions

15. Smoking, current or former smokers

16. Solid organ or blood stem cell transplant recipients

17. Substance use disorders

18. Tuberculosis

• Age 18 years of age or older who are at increased risk for COVID-19 exposure and transmission because of occupational or institutional setting based on individual benefits and risks:

1. First responders

2. Education staff

3. Food and Agriculture workers

4. Manufacturing workers

5. Corrections workers

6. US Postal Service workers

7. Public transit workers

8. Grocery store workers

For individuals who received the Jannsen Johnson & Johnson COVID-19 vaccine, individuals 18 years of age or older are eligible for a booster shot at 2 months or more after completion of their initial vaccination series.

 

HETEROLOGOUS OR "MIX AND MATCH" BOOSTER DOSES

The FDA has also authorized the use of each of the available COVID-19 vaccines as a heterologous (or “mix and match”) booster dose in eligible individuals following completion of primary vaccination with a different available COVID-19 vaccine. Some people may have a preference for the vaccine type that they originally received and others, may prefer to get a different booster. CDC’s recommendations now allow for this type of mix and match dosing for booster shots.

 

Additional Dose of Pfizer-BioNtech COVID-19 vaccine and the Moderna COVID-19 vaccine in MODERATELY OR SEVERELY IMMUNOCOMPROMISED individuals 

The administration of an additional (i.e. third dose) for certain individuals who are moderately or severely immunocompromised due to a medical condition or receipt of immunosuppressive medications or treatments is approved for both the Pfizer-BioNtech COVID-19 vaccine and the Moderna COVID-19 vaccine. 

The age groups authorized for an additional dose remain the same as those for the primary mRNA COVID-19 dose series (Pfizer: aged ≥12 years or Moderna: aged ≥18 years). 

According to the CDC, an estimated 2.7 percent of adults in the United States are immunocompromised. This proportionally equates to approximately 425,000 adults in NYS. Persons with immunocompromising conditions are more likely to get severely ill from COVID-19, are at a higher risk for prolonged SARS-CoV-2 infection and viral shedding, have increased viral evolution during infection and treatment (hospitalized patients), have low antibody/neutralization titers to SARS-CoV-2 variants, are more likely to transmit SARS-CoV-2 to household contacts, and are more likely to have breakthrough infection. Therefore, certain people who are moderately or severely immunocompromised due to a medical condition or receipt of immunosuppressive medications or treatments, should consult with their healthcare provider to discuss the benefits of an additional dose of an mRNA vaccine, and receive the additional vaccine dose if indicated.

Due to the risk of COVID-19 infection in this population, immunocompromised people should continue to be counseled regarding the potential for a reduced immune response after vaccination and the importance of additional protective measures, regardless of the decision to receive an additional dose of the COVID-19 vaccine. Prevention measures include wearing a mask, staying six feet apart from others they don’t live with, and avoiding crowds and poorly ventilated indoor spaces until advised otherwise by their healthcare provider. Close contacts of immunocompromised people should be strongly encouraged to be vaccinated against COVID-19.

The additional mRNA COVID-19 vaccine dose is to be administered at least 28 days after the completion of an initial 2 dose primary  mRNA COVID-19 vaccine series in immunocompromised individuals. 

Eligibility for Additional Doses of Pfizer-BioNTech or Moderna COVID-19 Vaccines 

Immunocompromised people who have completed a primary vaccine series (i.e., 2 - dose mRNA vaccine series [Pfizer-BioNTech and Moderna] or single dose of the Janssen vaccine) are considered fully vaccinated ≥2 weeks after completion of the series. However, an additional dose of an mRNA COVID-19 vaccine (at least 28 days following the last dose of the primary COVID-19 vaccine series) should be considered for people with moderate to severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments.

These conditions and treatments include but are not limited to:

• Active treatment for solid tumor and hematologic malignancies

• Receipt of solid-organ transplant and taking immunosuppressive therapy

• Receipt of CAR-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy)

• Moderate or severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome)

• Advanced or untreated HIV infection

• Active treatment with high-dose corticosteroids (i.e., ≥20mg prednisone or equivalent per day), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor-necrosis (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory

A person should not receive more than three mRNA COVID-19 vaccine doses.

 

The guidance above for an additional dose after an initial primary series is different than a “booster dose”. A “booster dose” is defined as an additional dose of vaccine administered when the initial sufficient immune response to a primary vaccine series is likely to have waned over time. 

Due to the risk of COVID-19 infection in this population, immunocompromised people should continue to be counseled regarding the potential for a reduced immune response after vaccination and the importance of additional protective measures, regardless of the decision to receive an additional dose of the COVID-19 vaccine. Prevention measures include wearing a mask, staying six feet apart from others they don’t live with, and avoiding crowds and poorly ventilated indoor spaces until advised otherwise by their healthcare provider. Close contacts of immunocompromised people should be strongly encouraged to be vaccinated against COVID-19.

 

Common COVID-19 Vaccine Questions

Side effects confirm the vaccine is working with your immune system

►Side effects may include pain at the injection site, tiredness, headache, muscle and joint pain or chills and fever

►Remember the vaccine does not contain the virus, so it cannot give you COVID-19

Why get the COVID-19 vaccine at Neergaard Pharmacy?

►We have years of experience safely administering vaccines, such as those for flu, shingles and pneumonia

►We offer easy, online scheduling for your COVID-19 vaccine 

►We have been a neighborhood pharmacy in Park Slope, Brooklyn for over 100 years

Who will be administering the COVID-19 Vaccine?

A Neergaard Pharmacist will be administering the COVID-19 vaccine.

What processes are in place to ensure timely and appropriate second dose administration?

All first and second doses of the COVID-19 vaccine will require an appointment. The second COVID-19 dose appointment will be scheduled after you receive your first dose by the vaccinating pharmacist. It is critical that you keep this appointment and complete the two dose series of the vaccine. Upon receiving your first dose, you will be provided with a mandated vaccine card with all relevant vaccination information. Neergaard Pharmacy has a detailed tracking system to make sure we know who received the COVID-19 vaccine and that they get the second dose on schedule. Detailed reporting of all vaccinations will be shared with all state and local public health authorities. 

How will vaccines be handled, distributed and tracked?

Neergaard Pharmacy has put into place essential logisitics, such as ensuring we have appropriate freezer capacity, to ensure that we can handle, distribute, store and track vaccine inventory. 

Will I be charged for the COVID-19 vaccine?

No, patients will not be charged for the vaccine or vaccine administration. The government will pay for the cost of the vaccine, and the healthcare provider who administers the vaccine will be reimbursed by the patient's insurance. 

Do I need an appointment to receive the COVID-19 vaccine?

Yes, an appointment is required to receive the COVID-19 vaccine at Neergaard Pharmacy. If you are unable to schedule an appointment online, please stop by one of our locations and we will assist you. 

What side effects should I expect after receiving the COVID-19 vaccine?

The most commonly reported side effects were pain at the injection site, tiredness, headache, muscle pain, chills, joint pain and fever. It is important to note that more people experienced these side effects after the second dose than after the first dose. It is therefore important for vaccinators and vaccine recipients to anticipate side effects after either dose, but even more so after the second dose. 

How is Neergaard Pharmacy prepared to treat potential allergic reactions to the COVID-19 vaccine?

Pharmacist immunizers are trained in the safe administration of COVID-19 vaccines authorized for use by the FDA, including identifying and treating allergic reactions. The vaccination procedure includes a patient screening checklist to assess the risk of reaction. All patients are monitored for 15 minutes after administration of the vaccine or longer for patients with a history of severe allergic reactions. Pharmacists at Neergaard Pharmacy are equipped with appropriate equipment and medications, such as epinephrine and antihistamines, to assess and treat adverse reactions. 

Which COVID-19 Vaccine will be available at Neergaard Pharmacy?

You will receive either the Pfizer-BioNTech COVID-19 vaccine, the Moderna COVID-19 vaccine or the Johnson & Johnson Janssen COVID-19 vaccine. 

What is the dosing schedule for the Pfizer-BioNTech COVID-19 vaccine?

The Pfizer-BioNTech COVID-19 vaccine is administered as a 2-dose series of 0.3mL each dose, 21 days apart, into the muscle. The Pfizer-BioNTech booster dose is a single dose of 0.3mL administered 6 months or more after the completion of the initial vaccination series. 

What is the dosing schedule for the Moderna COVID-19 vaccine?

The Moderna COVID-19 vaccine is administered as a 2-dose series of 0.5 mL each dose, 28 days apart, into the muscle. The Moderna booster dose is a single dose of 0.25mL administered 6 months or more after the completion of the initial vaccination series. 

What is the dosing schedule for the Johnson & Johnson Janssen COVID-19 vaccine?

The Johnson & Johnson Janssen COVID-19 vaccine is administered as a single one time dose of 0.5 mL, into the muscle. The Johnson & Johnson Janssen booster dose is a single dose of 0.5 mL administered 2 months or more after the completion of the primary vaccination.

What groups are eligible for COVID-19 vaccination at Neergaard Pharmacy?

ALL individuals age 12 and older are eligible to be vaccinated. 

According to the Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine, minors 12 years of age and older are authorized to receive such vaccine. HOWEVER, MINORS AGE 12 to 17 are NOT authorized to receive the Johnson & Johnson Janssen or Moderna vaccine. 

A minor is defined as an individual under the age of 18. Minors need parental or gaurdian consent to receive a COVID-19 vaccine, except in rare instance where the minor is part of a group to whom the law gives the right to consent to their own care (e.g. married minors, minors who are parents or pregnant, and minors in the military). 

In general, it is strongly encouraged that a parent or legal gaurdian accompany a minor age 12 to 17 to provide in person consent for vaccination at each dose. 

Where can I find more information on the Johnson & Johnson Janssen COVID-19 vaccine?

Visit  Janssen COVID-19 Vaccine EUA Fact Sheet for Recipients and Caregivers (fda.gov) for more information on the Johnson & Johnson Janssen COVID-19 vaccine. 

Where can I find more information on the Pfizer-BioNTech COVID-19 vaccine?

Visit Pfizer-BioNTech COVID-19 Vaccine EUA Fact Sheet for Recipients and Caregivers (fda.gov) for more information on the Pfizer-BioNTech COVID-19 vaccine. 

Where can I find more information on the Moderna COVID-19 vaccine?

Visit Moderna COVID-19 Vaccine EUA Fact Sheet for Recipients and Caregivers (fda.gov)

What is V-safe?

V-safe is a smartphone based tool that uses text messaging and web surveys to provide personalized health check-ins after you receive a COVID-19 vaccination. 

Visit https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/vsafe.html for more information on v-safe.

Will both Neergaard locations offer the COVID-19 vaccine?

Yes. You may schedule an appointment to receive the COVID-19 vaccine at both Neergaard 5th Avenue located at 454 5th Avenue and Neergaard 7th Avenue located at 120 7th Avenue.  

How do I schedule an appointment for the COVID-19 Vaccine at Neergaard Pharmacy?

You can schedule an appointment at either Neergaard location by clicking the "Schedule a Vaccine Appointment" button below and selecting the location you would like to receive the vaccine.  

 

5th Avenue Vaccine Appointment

7th Avenue Vaccine Appointment

 

 

 

 

 

Aa Aa Aa